Pharmacists
About
EASL recognises the important role of pharmacists in the care of patients with liver disease. Through their expertise in medicines optimisation, medication safety, patient counselling, and multidisciplinary collaboration, pharmacists contribute significantly to improving treatment outcomes and enhancing the quality of care. Their involvement across healthcare settings supports the safe and effective use of therapies, promotes adherence, and helps address the complex medication-related needs of people living with liver disease. By working closely with patients and healthcare professionals, pharmacists play a key role in advancing comprehensive, patient-centred liver care.
Meet the Task Force
Aim
The aim of the Pharmacy Task Force is to strengthen pharmaceutical care for people affected by liver disease by fostering multidisciplinary collaboration, advancing pharmacy practice, and supporting excellence in patient care across Europe.
- Developing educational and training initiatives in liver pharmacy, including dedicated sessions at the EASL Congress and contributions to EASL Studios and other educational activities
- Fostering a European network of pharmacy professionals involved in hepatology, promoting collaboration, knowledge exchange, research, and the sharing of best practices across countries and healthcare settings
- Collaborating with EASL committees, task forces, and external stakeholders to advance innovation, improve medication safety, support equitable access to therapies, and contribute to the development of high-quality pharmaceutical care for people living with liver disease
Explore the resources tailored to you
Pharmacy TF activities at EASL Congress
Pharmacy TF resources on EASL Campus
Discover the opportunities available for you
Excellence in Liver Care Award
The EASL Emerging Leader Award is an annual award, dedicated specifically to young fellows. Every year, the EASL Governing Board and Young Investigators Task Force select two YI Awardees, based on their international liver research achievements.
Membership
EASL supports Young Investigators by helping them attend EASL meetings. We offer two types of bursaries to the presenting authors only of the best accepted abstracts who are aged 35 or younger and/or are still in training.
Become a member
Unlock the full potential of being part of the EASL
community. As a member, you’ll gain access to
exclusive resources, reduced event fees, top-tier
journals, and professional development opportunities designed to support your career in hepatology
Each year, almost 300,000 people in Europe die prematurely due to problems of the liver. Many of them could have lived longer and healthier lives. Because today, in most European countries, there is good access to secondary care. In most cases, liver disease can be prevented. Prevention is the best cure that we have. So together, we need to raise more awareness of the preventable and treatable nature of many chronic illnesses.
Ursula Von der Leyen, President of the European Commission
Why a second EASL-Lancet Commission? We have seen a remarkable response to the recommendations from our first Commission report, not only within the hepatology community, but also from other health care sectors, primary care in particular, in shifting the focus towards prevention, early detection and early interventions. But work remains, particularly related to structural drivers of liver-related mortality, most markedly the fragmented landscape of alcohol policies in Europe. This second commission is dedicated to ensuring that actions continue, to maximise implementation of the changes we proposed, alongside data and grass-root indicators to measure progress in this implementation.
Tom Hemming Karlsen, Steering Committee Co-Chair of the EASL-Lancet Commission
To improve the lives of all people around Europe is the ultimate goal of all EASL activities. Embarking on a second Commission allows the liver health community to identify those problems in the field that are in most need of bold and tangible solutions.
Aleksander Krag, Former EASL Secretary General
At EASL, we are well placed to support the education of clinicians on the fundamentals and potential applications of AI. We can help foster connections between AI researchers, clinical trial developers, and policymakers, and contribute to a shared understanding of how AI might enhance patient care. By recommending validated tools in our guidelines and supporting the development of central, unbiased data repositories, we can play a constructive role in advancing trustworthy and effective AI in hepatology.
Sabela Lens, EASL Scientific Committee Member